Definition of key variables for the induction of optimal NY-ESO-1 - Specific T cells in HLA transgene mice

Journal of Immunology

Volumn 185, Issue 6, 2010, Pages 3445-3455

  Johannsen, Alexandre ^a   Genolet, Raphaël ^a   Legler, Daniel F ^c   Luther, Sanjiv A ^b   Luescher, Immanuel F ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF KONSTANZ   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; EPITOPE; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN; HLA DR1 ANTIGEN; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NY ESO 1 ANTIGEN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CELL MATURATION; CIRCULATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNIZATION; IN VITRO STUDY; LYMPH NODE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TRANSGENIC MOUSE; TUMOR CELL; UPREGULATION;

EID: 78649884294     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001397     Document Type: Article

References (50)

1. Melief, C. J. 2008. Cancer immunotherapy by dendritic cells. Immunity 29: 372-383.
2. Pilla, L., L. Rivoltini, R. Patuzzo, A. Marrari, R. Valdagni, and G. Parmiani. 2009. Multipeptide vaccination in cancer patients. Expert Opin. Biol. Ther. 9: 1043-1055.
3. + T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126: 909-918.
4. Pittet, M. J., V. Rubio-Godoy, G. Bioley, P. Guillaume, P. Batard, D. Speiser, I. Luescher, J. C. Cerottini, P. Romero, and A. Zippelius. 2003. α3 Domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J. Immunol. 171: 1844-1849.
5. Boissonnas, A., A. Scholer-Dahire, L. Fetler, and S. Amigorena. 2009. Multiphoton imaging of cytotoxic T lymphocyte-mediated antitumor immune responses. Curr. Top. Microbiol. Immunol. 334: 265-287.
6. Fujii, S., K. Liu, C. Smith, A. J. Bonito, and R. M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199: 1607-1618.
7. Hendriks, J., L. A. Gravestein, K. Tesselaar, R. A. van Lier, T. N. Schumacher, and J. Borst. 2000. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1: 433-440.
8. Krieg, A. M. 2007. Development of TLR9 agonists for cancer therapy. J. Clin. Invest. 117: 1184-1194.
9. Wurzenberger, C., V. H. Koelzer, S. Schreiber, D. Anz, A. M. Vollmar, M. Schnurr, S. Endres, and C. Bourquin. 2009. Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo. Cancer Immunol. Immunother. 58: 901-913.
10. + T cell expansion by dendritic cells. J. Immunol. 184: 591-597.
11. H response. Hum. Immunol. 61: 764-779.
12. + T-cell help. Nature 462: 510-513.
13. Gerner, M. Y., K. A. Casey, and M. F. Mescher. 2008. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J. Immunol. 181: 155-164.
14. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
15. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
16. + T cells. Immunol. Rev. 211: 81-92.
17. + T cell responses. J. Immunol. 181: 7445-7448.
18. + memory T cells. Nature 441: 890-893.
19. + T cell-dendritic cell interaction. Nature 440: 890-895.
20. Beuneu, H., Z. Garcia, and P. Bousso. 2006. Cutting edge: cognate CD4 help promotes recruitment of antigen-specific CD8 T cells around dendritic cells. J. Immunol. 177: 1406-1410.
21. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 206: 849-866.
22. + T cell responses. Nat. Immunol. 8: 921-930.
23. Grigorova, I. L., S. R. Schwab, T. G. Phan, T. H. Pham, T. Okada, and J. G. Cyster. 2009. Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells. Nat. Immunol. 10: 58-65.
24. i- coupled receptors to promote T cell egress. Immunity 28: 122-133.
25. Pajot, A., M. L. Michel, N. Fazilleau, V. Pancré, C. Auriault, D. M. Ojcius, F. A. Lemonnier, and Y. C. Lone. 2004. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. 34: 3060-3069.
26. Chen, J. L., P. R. Dunbar, U. Gileadi, E. Jäger, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y. T. Chen, A. Knuth, et al. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165: 948-955.
27. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1751-1759.
28. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
29. + memory T cells. J. Exp. Med. 186: 859-865.
30. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171: 27-31.
31. Jing, H., J. H. Yen, and D. Ganea. 2004. A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2. J. Biol. Chem. 279: 55176-55186.
32. Link, A., T. K. Vogt, S. Favre, M. R. Britschgi, H. Acha-Orbea, B. Hinz, J. G. Cyster, and S. A. Luther. 2007. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8: 1255-1265.
33. Britschgi, M. R., A. Link, T. K. Lissandrin, and S. A. Luther. 2008. Dynamic modulation of CCR7 expression and function on naive T lymphocytes in vivo. J. Immunol. 181: 7681-7688.
34. + T cell tolerance and permits effective immunity. Immunity 29: 934-946.
35. + T-cell immunity by immature dendritic cells in a vaccination setting. Blood 113: 5167-5175.
36. + T cells in response to MIP-1a and MIP-1b. Science 260: 355-358.
37. + responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl. Acad. Sci. USA 101: 9363-9368.
38. Zou, W., J. Borvak, F. Marches, S. Wei, P. Galanaud, D. Emilie, and T. J. Curiel. 2000. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J. Immunol. 165: 4388-4396.
39. Luther, S. A., and J. G. Cyster. 2001. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2: 102-107.
40. Karpus, W. J., N. W. Lukacs, K. J. Kennedy, W. S. Smith, S. D. Hurst, and T. A. Barrett. 1997. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol. 158: 4129-4136.
41. Jones, E., D. A. Price, M. Dahm-Vicker, V. Cerundolo, P. Klenerman, and A. Gallimore. 2003. The influence of macrophage inflammatory protein-1α on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109: 68-75.
42. - dendritic cell maturation and activation following viral infection of the central nervous system: implications for a role in T cell activation. Virology 327: 8-15.
43. Song, R., S. Liu, and K. W. Leong. 2007. Effects of MIP-1α, MIP-3α, and MIP-3β on the induction of HIV Gag-specific immune response with DNA vaccines. Mol. Ther. 15: 1007-1015.
44. + T-cell recruitment. Cancer Res. 69: 3077-3085.
45. Karpus, W. J., and K. J. Kennedy. 1997. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J. Leukoc. Biol. 62: 681-687.
46. + T cells. Eur. J. Immunol. 31: 2411-2420.
47. Cyster, J. G. 2005. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu. Rev. Immunol. 23: 127-159.
48. + T cells. J. Immunol. 178: 778-787.
49. Contento, R. L., B. Molon, C. Boularan, T. Pozzan, S. Manes, S. Marullo, and A. Viola. 2008. CXCR4-CCR5: a couple modulating T cell functions. Proc. Natl. Acad. Sci. USA 105: 10101-10106.
50. Caballero, O. L., and Y. T. Chen. 2009. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100: 2014-2021.